Clinical Trials Sponsored by Daiichi Sankyo

Total 799 results

Daiichi Sankyo
Daiichi Sankyo, Inc.

Active, not recruiting

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

Glioma

Japan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
Daiichi Sankyo Co., Ltd.

Recruiting

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Solid Tumor | Metastatic Solid Tumor | Advanced Cancer

Japan, United States, Canada
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT (PLX3397)

Tenosynovial Giant Cell Tumor

Taiwan, China
Daiichi Sankyo

Recruiting

A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors

Advanced Solid Tumor

United States
Daiichi Sankyo

Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast Cancer

China
Daiichi Sankyo

Recruiting

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Netherton Syndrome

France
Daiichi Sankyo

Recruiting

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

COPD Exacerbation Acute

China
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Daiichi Sankyo Germany

Completed

SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®

Hypercholesterolemia | Mixed Dyslipidemia

Germany
Daiichi Sankyo Turkey, a Daiichi Sankyo Company
Daiichi Sankyo, Inc.

Completed

Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR)

Atrial Fibrillation

Turkey
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo

Active, not recruiting

DS-3201b in Participants With Lymphomas

Lymphoma, Malignant | Non-hodgkin Lymphoma

United States, Japan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Austria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI)

Cardiovascular Diseases | Dyslipidemia | Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Finland, Netherlands, Spain, Belgium, Sweden, Austria, United Kingdom, Switzerland, Denmark, France, Germany, Portugal, Italy, Ireland
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo

Active, not recruiting

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Melanoma

Korea, Republic of, China
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Adult T-cell Leukemia/Lymphoma

Japan
Daiichi Sankyo

Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States, Japan
Daiichi Sankyo

Active, not recruiting

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

EGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
Daiichi Sankyo

Completed

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan (EUROPA T-DXd)

HER2-positive Breast Cancer

Spain, Ireland, Italy
Daiichi Sankyo

Available

Medical Access Program for Patritumab Deruxtecan

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

United States
Daiichi Sankyo

Completed

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

HER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (MILOS-Spain)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Isolated Systolic Hypertension in the Elderly and Very Elderly

Isolated Systolic Hypertension

Germany
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Daiichi Sankyo

Recruiting

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
Daiichi Sankyo

Completed

A Dose Finding Study of VN-0200

Respiratory Syncytial Virus Infections

Japan
Daiichi Sankyo

Terminated

DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

United States, Japan
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Breast Cancer

China, United States, Spain, Hungary, Israel, Korea, Republic of, Taiwan, Belgium, Austria, Russian Federation, Switzerland, Portugal, France, Canada, Italy, United Kingdom, Greece, Japan, Germany, Sweden
Daiichi Sankyo
Daiichi Sankyo Korea Co., Ltd.

Active, not recruiting

An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Dyslipidemia

Korea, Republic of
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Belgium, Australia, Czechia, Japan, Brazil, France, United Kingdom, Turkey, Greece, Germany
Daiichi Sankyo Co., Ltd.

Completed

Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Gastric Cancer

Korea, Republic of, Hong Kong, Taiwan, China
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

Covid19

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
Daiichi Sankyo Co., Ltd.

Completed

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

Healthy Subjects | Pharmacokinetics | Drug-drug Interaction | Quizartinib

United States
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects

Respiratory Syncytial Virus Infections

Japan
Daiichi Sankyo Co., Ltd.

Terminated

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis

Atopic Dermatitis

Japan
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Leukemia, Myeloid, Acute

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors

Solid Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment

Non-valvular Atrial Fibrillation

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery

Venous Thromboembolism

Japan
Daiichi Sankyo Co., Ltd.

Completed

DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation

Stroke | Atrial Fibrillation

Taiwan, Korea, Republic of, Singapore, China
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Deep Vein Thrombosis | Venous Thromboembolism | Total Knee Arthroplasty

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.

Completed

An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp

Type 2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Multinational Phase III Study of CS-8958 (MARVEL) (MARVEL)

Influenza, Human

Taiwan, Japan, Korea, Republic of, China
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-1123a in Advanced Solid Tumours

Advanced Solid Malignant Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Patients With Severe Hypertension

Severe Hypertension

Japan

Clinical Trials Sponsored by Daiichi Sankyo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations